Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

iS Clinical

Also known as: IS Clinical, Innovative Skincare

iS Clinical is a professional skincare brand offering cleansers, serums, moisturisers, sunscreens and facial treatments. Its products combine cosmetic ingredients for different appearance and skincare needs. Evidence and suitability must be assessed for the particular formula or treatment.

In plain English — iS Clinical offers everyday skincare, targeted serums and professional facials. The range includes different products for cleansing, hydration and skin appearance, so selection starts with the person's needs and the exact formula. Retinol products need particular caution during pregnancy or breastfeeding, when clinical guidance advises avoiding them.

Evidence status

Manufacturer-supported

Product-specific commercial human data and laboratory research. A company report describes improvements after a two-week cleanser-and-hydrator programme in 40 subjects, with limited published methods. A separate manufacturer-funded paper studies retinol mixtures in reconstructed skin, not people using a retail product. Current labels and clinical guidance require product-specific interpretation, particularly for retinol in pregnancy.

What iS Clinical is#

iS Clinical is a professional skincare brand whose published history dates its founding to 2000, by Bryan Johns and Alec Call. It organises its range around cleansing, treatment, hydration and protection.[1, 2] Products include cleansers, serums, moisturisers and sunscreens, alongside professional facial services.[2, 6, 7, 14]

Official terms identify Science of Skincare, LLC, doing business as iS Clinical or Innovative Skincare.[1, 2] The current UK site and professional partner material identify Harpar Grace International in the UK supply relationship; Companies House confirms Harpar Grace International Ltd, company 08479007.[3, 4, 5] The UK supplier and the US brand operator are distinct corporate roles.

The subject here is the particular brand and its evidence. Retinoids, hyaluronic acid and peptides explain the wider ingredient science.

Use of iS Clinical in aesthetic practice#

The practical starting point is the client’s concern and current routine. A cleanser, a moisturiser and a targeted retinol product have different purposes even when they share a brand. Current US examples include Daily Dynamic Hydrator and Retinol Emulsion 0.3, with different ingredient mixtures and suitability questions.[2, 6, 7, 14]

Professional services also differ. Fire & Ice pairs an intensive resurfacing masque with a rejuvenating masque; the manufacturer describes warming and cooling sensations. Prodigy Peel and Prodigy Peel Pro are separate systems, described by the company as superficial and superficial-to-medium respectively.[14, 15, 16] The broader menu includes Harmony, Honey Enzyme, Foaming Enzyme and other targeted services.[14]

For product supply, GB and NI have separate cosmetics guidance covering responsible persons, safety information, notification and claims. NI follows the relevant EU/Windsor framework; GB guidance applies to England, Scotland and Wales.[18, 19, 20]i In the US, FDA generally does not pre-approve cosmetics, apart from colour additives, and manufacturers are responsible for safety.[20]A product’s regulatory category and the evidence for a particular benefit are separate questions.

Contraindications and cautions#

Retinol during pregnancy and breastfeeding

AAD public guidance advises avoiding retinol and retinyl-palmitate products during pregnancy or breastfeeding.[12] The current US Retinol Emulsion 0.3 page asks pregnant, pregnancy-planning or nursing users to consult their physician, while the current UK explanation makes a pregnancy/breastfeeding safety claim.[7, 8, 12]i Follow appropriate clinical advice for the individual rather than a blanket brand assurance; the precaution does not itself demonstrate that this particular product has caused fetal harm.

The evidence behind the reassurance deserves an accurate account. A historical, manufacturer-authored pregnancy white paper cites Nohynek’s 2006 pharmacokinetic study. Its primary abstract describes two groups of 14 women, using 0.30% retinol or 0.55% retinyl-palmitate cream over approximately 3,000 cm² for 21 days. Measured plasma retinoids did not change from baseline. The record is indexed as a randomised trial, although the retrieved abstract does not explain allocation. The lead author was affiliated with L’Oréal R&D; separate funding was unavailable in the retrieved abstract.[10, 11]i

That is a relevant blood-level finding, but it was not a pregnancy-outcome study or a test of the current iS Clinical emulsion. Unchanged measured blood concentrations are not proof of absolute zero absorption or established fetal safety.[10, 11]i

Current skin condition and formulation

The manufacturer’s retinol presentation notes identify unmanaged or undiagnosed inflammatory skin as a suitability concern; the current US product page also gives a sun-sensitivity warning.[7, 9] An active eruption should be assessed before selecting a targeted product or resurfacing service.

Check the complete ingredients for a relevant allergy history. The retrieved US hydrator and retinol labels both list fragrance; that is an item-specific fact, not a claim that every product contains it.[6, 7]

Clinical uses and the evidence behind them#

Hydration and visible facial lines

The manufacturer reports a study of 40 subjects over two weeks using Daily Dynamic Hydrator together with Cleansing Complex. The company describes improvements in measured hydration, elasticity and the appearance of facial lines.[6] This is a positive report about a particular short programme.

The available source is the manufacturer’s product-page study summary, not an independently retrieved peer-reviewed report. It does not provide ages, sex distribution, phototypes, a comparator, measurement instruments or confidence intervals. Those missing details limit appraisal and generalisation.[6]

Targeted topical care

Current US Retinol Emulsion 0.3 information describes a combination of retinol, bakuchiol, ectoin, squalane and hyaluronate. Daily Dynamic Hydrator includes peptides, hyaluronate and plankton extract among its ingredients.[6, 7]These are current formulation descriptions for those market-specific products, useful when matching a product to a person’s routine and tolerance.

The brand’s published laboratory research provides additional information about proposed mechanisms; it is discussed separately below so the human observations and reconstructed-skin experiments remain distinguishable.[13]

Professional facial and peel services

The manufacturer’s menu describes services aimed at skin appearance and comfort, with different masques, products and treatment purposes.[14, 15, 16]A Fire & Ice appointment and a Prodigy Peel Pro procedure should therefore be assessed as their actual named interventions. General procedural education belongs in the chemical-peel guide, alongside the current instructions for the particular system.

Selecting an iS Clinical product or treatment#

Choose a specific purpose, then the product or service that fits the assessed skin, existing routine and relevant cautions. Record the market-specific name and current ingredient list: regional advice and formulation information should be checked against the actual product supplied.[6, 7, 8, 9]

For a professional service, establish which facial or peel is proposed, its current manufacturer requirements, expected skin response and route to help if a reaction occurs. The treatment name alone does not substitute for individual assessment.[14, 15, 16, 17]

For a claim of improvement, ask what was assessed: a human skin measurement, a client’s perception, or a laboratory marker. That distinction helps align the choice with a realistic, reviewable goal.[6, 13]

Adverse effects and their management#

Cosmetic products can cause irritant or allergic contact dermatitis. Symptoms can include itching, redness or colour change, dryness, cracking or blistering; a formula’s individual ingredients and other recent exposures matter when assessing the cause.[6, 7, 17]i

Stop a suspected provoking exposure and arrange medical review for persistent, recurrent or severe symptoms. Keep the exact product, ingredient list and timing available for that assessment.[6, 7, 17]i This general advice does not establish a measured adverse-event rate for iS Clinical or identify a particular ingredient as the cause.

The retinol product’s own caution information and the instructions for a professional treatment remain relevant to expected reactions and suitability.[7, 9, 15, 16]

Referral and scope boundaries#

An undiagnosed inflammatory eruption, persistent dermatitis or symptoms beyond the practitioner’s competence require appropriate clinical assessment before further active products or a resurfacing procedure.[7, 9][6, 7, 17]i The perioral dermatitis, rosacea and acne vulgaris entries explain important clinical distinctions.

Pregnancy-related retinol questions should be referred to the person’s clinician where advice is unclear or conflicting. Product training or a distributor statement does not replace that clinical decision.[7, 8, 12]i

Mechanism of action#

The brand combines several mechanisms through different ingredients and formulations. Its moisturiser and retinol product contain different mixtures; a single brand-wide mechanism would be misleading.[6, 7] The more specific research question is how a particular mixture behaves in a defined model.

DeHaven and colleagues’ 2025 in-vitro paper used reconstructed full-thickness human skin, with four cultures per group. The researchers tested retinol/additive mixtures in saline, using a principal 48-hour analysis with additional gene-expression checks at selected time points. They reported changes in gene and protein markers related to skin circadian pathways.[13]

The work was funded by Innovative Skincare. DeHaven and Johns were manufacturer-affiliated, and Wheeler and Langerveld were affiliated with Genemarkers.[13]

Commonly misstated claims#

Gene markers and clinical rejuvenation

Claim heard:“Changing skin genes in the laboratory proves that the product reverses ageing in clients.”

Literature finding: The circadian paper measures responses in reconstructed skin and identifies human/clinical investigation as further work.[13]i

Supported statement: A laboratory marker change can support a mechanistic hypothesis; it does not by itself measure visible rejuvenation or DNA repair in a person.

Programme results and individual ingredients

Claim heard:“The hydrator study proves that one advertised ingredient produced the improvement.”

Literature finding:The company’s report describes the finished hydrator used with a cleanser. It does not include separate arms isolating a peptide, plankton extract or another ingredient.[6]i

Supported statement: The reported observation belongs to the studied product programme, not to an untested isolated component.

Treatment names and procedure equivalence

Claim heard:“Fire & Ice and Prodigy are the same peel under different names.”

Literature finding: The manufacturer describes distinct masque and peel systems, and separately describes Prodigy and Prodigy Pro.[14, 15, 16]

Supported statement: Identify the actual service and its instructions; a shared brand does not make different interventions interchangeable.

Areas of remaining uncertainty#

  • Durability of a useful effect: longer follow-up would help place the short hydrator report in the context of ongoing care and client priorities.[6]i
  • Relevance to different clients: more complete human study reporting would help assess applicability across age, skin type and existing routine.[6]
  • Translation of the laboratory findings: human studies using a clearly identified finished formula are needed to connect the circadian markers with patient-important outcomes.[13]i

Frequently asked questions#

Does iS Clinical mean one particular active ingredient?

No. It is a brand containing many formulas and services. For example, the hydrator and retinol emulsion have different ingredient combinations and purposes.[2, 6, 7, 14]

Who supplies the brand in the UK?

Current UK-site and professional partner documents identify Harpar Grace International. Check the authorised supplier and actual product details when purchasing.[3, 4, 5]

What should be clarified before booking a facial?

The exact service, the products involved, the intended outcome and any relevant skin or medical concern. Fire & Ice and the Prodigy systems have different descriptions and instructions.[14, 15, 16, 17]

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. iS Clinical. iS+ Benefits terms and conditions. Accessed 16 September 2026.Tier 4Supports: Exact operator wording: Science of Skincare, LLC, doing business as iS Clinical or Innovative Skincare; does not establish ultimate equity ownership.Funding / interest: Commercial company terms.
  2. iS Clinical. Our story. Accessed 16 September 2026.Tier 4Supports: Company account of 2000 founding by Bryan Johns and Alec Call, product categories and Cleanse–Treat–Hydrate–Protect organisation.Funding / interest: Manufacturer history and portfolio description; promotional efficacy assertions are not independent evidence.
  3. iS Clinical UK. Privacy policy. Accessed 16 September 2026.Tier 4Supports: UK site's Harpar Grace International controller/contact identity.Funding / interest: Commercial UK-site privacy publication.
  4. Harpar Grace International. iS Clinical professional partner information. Accessed 16 September 2026.Tier 4Supports: Current UK commercial supply/partner relationship and professional/homecare range; exclusivity and ultimate ownership are not established by this page.Funding / interest: Commercial distributor/partner material.
  5. Companies House. Harpar Grace International Ltd, company 08479007. Accessed 16 September 2026.Tier 1Supports: Active registered UK supplier identity; incorporation on 8 April 2013. Not proof of brand ownership or distribution exclusivity.Funding / interest: Public corporate register.
  6. iS Clinical. Daily Dynamic Hydrator: product information and study footnotes. Accessed 16 September 2026.Tier 4Supports: Company-reported 40-subject, two-week study using hydrator with Cleansing Complex, improved hydration/elasticity and facial-line appearance. Limited methods; current ingredients include peptides, hyaluronate, plankton extract and fragrance.Funding / interest: Manufacturer-published clinical summary; full sponsorship, investigators and methods not supplied. Not an independently retrieved peer-reviewed study.
  7. iS Clinical US. Retinol Emulsion 0.3. Current product information accessed 16 September 2026.Tier 4Supports: Current US retinol/bakuchiol/ectoin/squalane/hyaluronate/fragrance formula; asks pregnant, pregnancy-planning or nursing users to consult their physician, and gives sun-sensitivity warning.Funding / interest: Manufacturer technical product label.
  8. iS Clinical UK. Retinol Emulsion. Current UK information accessed 16 September 2026.Tier 4Supports: UK distributor's current explicit non-systemic/pregnancy/breastfeeding safety wording for Retinol+ Emulsion 0.3; evidence of the claim, not clinical proof of it.Funding / interest: Commercial UK product explanation.
  9. iS Clinical. Retinol Emulsions: speaker notes. September 2023 document; accessed 16 September 2026.Tier 4Supports: Manufacturer presentation identifies retinol formulations, encapsulation and unmanaged/undiagnosed inflammatory-skin caution; asserts non-systemic behaviour but gives no pharmacokinetic dataset.Funding / interest: Manufacturer educational/presentation material, not an independently published clinical trial.
  10. DeHaven C. Products During Pregnancy and Nursing. Science of Skincare/iS Clinical white paper, 2014/2016 copyright versions. Accessed 16 September 2026.Tier 4Supports: Historical company position cites Nohynek 2006 for topical vitamin-A pharmacokinetics; despite its label, this is a narrative statement rather than an original pregnancy trial.Funding / interest: Manufacturer-authored by the company's clinical director; retained on a regional brand site.
  11. Nohynek GJ, Meuling WJA, Vaes WHJ, et al. Repeated topical treatment, in contrast to single oral doses, with Vitamin A-containing preparations does not affect plasma concentrations of retinol, retinyl esters or retinoic acids in female subjects of child-bearing age. Toxicol Lett. 2006;163(1):65–76. doi:10.1016/j.toxlet.2005.09.029. PMID:16243460.Tier 2Supports: Indexed as an RCT; original abstract retrieved through Europe PMC does not describe allocation. Two groups of 14 women, 21-day topical retinol/palmitate exposure, no measured plasma-retinoid change versus baseline; later oral-dose component also present. Not a pregnancy-outcome study or current iS-product trial.Funding / interest: Lead author affiliated with L'Oréal Research and Development. Separate funding and complete conflicts unavailable in the retrieved primary abstract; independence is not inferred.
  12. American Academy of Dermatology. What can treat large facial pores? Accessed 16 September 2026.Tier 4Supports: Patient guidance advises avoiding retinol and retinyl-palmitate products during pregnancy/breastfeeding; precautionary guidance, not proof of harm from every product.Funding / interest: Professional-association patient guidance; no product sponsorship stated.
  13. DeHaven C, Wheeler S, Langerveld A, Johns CB. Regulation of dermal circadian pathways by a novel topical formulation. Int J Cosmet Sci. 2025;47(1):123–133. doi:10.1111/ics.13017. PMID:39219101.In vitroTier 3Supports: Reconstructed full-thickness human skin, four cultures per group, retinol/additive mixtures in saline, gene/protein endpoints; not volunteers or a retail-product human outcome trial.Funding / interest: Funded by Innovative Skincare. DeHaven and Johns were manufacturer-affiliated; Wheeler and Langerveld were affiliated with Genemarkers.
  14. iS Clinical. Professional treatments. Accessed 16 September 2026.Tier 4Supports: Facial portfolio includes Fire & Ice, Harmony, Honey Enzyme, Foaming Enzyme, Exfoliating Clear Skin, Flash Brightening and Prodigy systems.Funding / interest: Manufacturer service menu.
  15. iS Clinical. Fire & Ice facial. Accessed 16 September 2026.Tier 4Supports: Manufacturer describes an intensive resurfacing masque followed by a rejuvenating masque and warming/cooling sensations. Not a guaranteed zero-downtime result.Funding / interest: Manufacturer treatment description.
  16. iS Clinical. Prodigy Peel systems treatment. Accessed 16 September 2026.Tier 4Supports: Company distinguishes Prodigy Peel as superficial and Prodigy Peel Pro as superficial-to-medium; named system descriptions, not independently measured penetration in every client.Funding / interest: Manufacturer professional-treatment material.
  17. NHS. Contact dermatitis. Reviewed 3 May 2023; accessed 16 September 2026.Tier 4Supports: Cosmetic irritant/allergic dermatitis, trigger assessment and medical review for persistent, recurrent or severe symptoms.Funding / interest: NHS patient information; no commercial sponsor stated.
  18. OPSS. Regulation 2009/1223 and Cosmetic Products Enforcement Regulations 2013: Great Britain. Accessed 16 September 2026.Tier 1Supports: GB cosmetic safety, responsible-person, information-file, notification and product-claim responsibilities.Funding / interest: Official government regulatory guidance.
  19. OPSS. Regulation 2009/1223 and Cosmetic Products Enforcement Regulations 2013: Northern Ireland. Accessed 16 September 2026.Tier 1Supports: NI/EU cosmetic requirements under Windsor arrangements; distinct from GB guidance.Funding / interest: Official government regulatory guidance.
  20. US Food and Drug Administration. Cosmetics and pregnancy. Accessed 16 September 2026.Tier 1Supports: US cosmetics generally have no FDA premarket approval, except colour additives; manufacturers are responsible for safety and pregnant users should ask their clinician about concerns.Funding / interest: Official US regulatory information; not a UK authorisation.